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Abstract 
 
Eleven new steroidal mono- and bis(semicarbazones) 2a–e,  4d and 3a–e have been prepared 
starting from various 3-oxo-α,β-unsaturated steroids. Mono-semicarbazones 2a–e were 
further  subjected to ethyl chloroacetate in boiling absolute ethanol but, instead of expected 
intramolecular cyclocondensation reaction products, the new carbazate esters 5a‒e were 
obtained. The structures of all synthesized compounds and identification of each E/Z isomer 
were deduced by elemental analysis, HRMS, NMR, and IR spectroscopy. Preliminary 
screening for the cytotoxic activity in vitro of the new compounds has been conducted against 
three cancer cell lines, K562, Jurkat and HeLa cells. HeLa cells were the most sensitive while 
K562 cells were the least sensitive to the cytotoxic action of the novel steroid derivatives. 
Compounds 2e, 3c and 5e were found to have the best but still moderate cytotoxic effects. All 
tested compounds showed very weak antimicrobial activities. These results demonstrate that 
the replacement of thioxo group with carbonyl group in steroidal hydrazone derivatives 
resulted in decrease in their biological activity. 
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Highlights 
 The synthesis of new steroidal mono- and bis(semicarbazones) was performed 
 The new carbazate esters were obtained 
 The structures were determined by IR, NMR, HRMS and elemental analysis 
 The antimicrobial and cytotoxic activities of the compounds were tested 
 The replacement of thioxo group with carbonyl group in steroidal hydrazone 
derivatives resulted in decrease in their biological activity 
 
  
1. Introduction 
 
In recent years transformations of steroidal molecules have become one of the main area 
of interest in steroidal chemistry research.  As a very important group of natural compounds, 
steroids play an essential role in some of the most fundamental biological functions in the 
human body [1]. Also, steroid based chemotherapeutics are widely used in the 
pharmacological industry. Therefore, certain functional and structural modifications of the 
steroid core can be very useful, giving compounds with new and more pronounced biological 
activity. It has been found so far that many of such modified steroidal derivatives, showing 
significant antibacterial, antiviral, antitumor or other biological activities, have been 
developed as drugs and anticancer agents [2]. For example, modifications involving changes 
in A- and A- and D-rings of steroidal molecule by the addition of heteroatom (N, S, O) or new 
functional group, have been reported to enhance the biological activities of steroidal 
compounds [3-8]. Within these studies, synthesis of new steroidal thiosemicarbazones, 
semicarbazones and hydrazones have received extensive attention of scientists [9-16].  
 Тhe transformations of  A- and A- and D-ring in series of 3-oxo-α,β-unsaturated steroids 
has also become the main topic of our research lately. Thus, earlier we reported a few papers 
on synthesis and biological activity of several sulfur-, and sulfur and phosphorus-containing 
steroidal compounds, including  3-thiones and 3,17-dithiones [17], new acyclic  steroidal 
dimers where two identical steroid molecules were joined via ring A  ring A connection 
through various spacer groups (sulphur, 1,2,4-trithiolanes, phosphorotrithioates), as well as 
17-spiro-, and 17-substituted-1,3,2-oxathiaphospholane-2-sulfides [18-20]. Recently we 
reported preparation and configuration analysis of new steroidal mono- and 
bis(thiosemicarbazones), and corresponding derivatives with heterocyclic rings, 3-spiro and 
3,17-dispiro thiadiazolines (mono- and bis(1,3,4-thiadiazolines)) [21] and  3- and 3,17-
substituted mono- and bis(thiazolidin-4-ones) [1] and their in vitro cytotoxic activity. It was 
found that 3-thiosemicarbazones and almost all examined thiazolidinone derivatives (both 
mono and bis) exerted selective concentration-dependent cytotoxic activities on six tested 
malignant cell lines. Among them HeLa and K562 cells were the most sensitive to the 
cytotoxic effects of these compounds. Additionally, these compounds showed a strong anti-
angiogenic acitivity.   
 Based on these studies and in the context of the importance of developing new cancer 
drugs, the present work has been designed to synthesize new derivatives of 3-oxo-α,β-
  
unsaturated steroids, to evaluate and compare their in vitro cytotoxic activity with those 
reported earlier. Also, the aim of this paper was to examine the effect of heteroatom, S and O, 
incorporated in our investigated steroidal derivatives on their biological activity. For that 
purpose and as a continuation of our previous reserarch, in our current work we describe 
synthesis of new steroidal mono- and bis(semicarbazones) and corresponding derivatives, 
together with preliminary screening for their antimicrobial and cytotoxic activity. 
 
2. Experimental 
 
2.1. Chemistry  
All synthetic reagents were analytically pure and solvents were prepared according to the 
standard procedures before being used. The starting steroid derivatives were purchased from 
Galenika AD (Belgrade, Serbia) and were recrystallized from a suitable solvent. Flash column 
chromatography (FCC) was carried out with Merck silica gel 0.040‒0.063 mm. Thin layer 
chromatography (TLC) was carried out on precoated silica gel 60 F254 plates. Melting points 
were determined on a Digital melting point WRS-1B apparatus and are uncorrected. IR 
spectra were recorded with Perkin-Elmer FT-IR 1725X spectrophotometer. 
1
H and 
13
C NMR 
spectra were recorded in DMSO-d6 and/or CDCl3 with Bruker Avance 500 (
1
H  at 500 MHz, 
13
C at 125 MHz) and Varian Gemini-200 spectrometers (
1
H at 200 MHz, 
13
C at 50 MHz) and 
TMS was used as an internal reference. Chemical shifts (δ) are measured in ppm and coupling 
constants (J) in Hz.  The homonuclear 2D (NOESY, COSY) and the heteronuclear 2D 
1
H-
13
C 
spectra (HSQC, HMBC) were recorded with the usual settings. The high-resolution mass 
spectra (HRMS) were taken with Agilent 6210 TOF LC/MS or Thermo Scientific HESI-LTQ 
Orbitrap XL spectrometers. Elemental analyses were performed on Vario EL III. 
 
2.1.1. General procedure for the synthesis of semicarbazones and bis(semicarbazones) 
To a solution of steroid (1a‒e) (3 mmol) in dried ethanol (150 mL) semicarbazide (4 
mmol) was added. The solution was then allowed to reflux for 1‒2 h under stirring. After 
completion of the reaction (monitored by TLC), the solvent was removed under reduced 
pressure. The residue was chromatographed by FCC using the indicated solvent system. In 
most of the cases the products were obtained as inseparable mixtures of E and Z 
diastereoisomers. 
 
  
2.1.1.1. 19-Norandrost-4-ene-3,17-dione 3-semicarbazone (2a). The title compound was 
obtained starting from 19-norandrost-4-ene-3,17-dione (1a) (815 mg). Elution with 
CH2Cl2/MeOH (100/2.5) gave 2a (466 mg, 47.1%). Rf = 0.28 (CH2Cl2/MeOH = 20:1). Mp > 
200 °C (decomp.). IR (ATR/cm
-1
): 3422 and 3146 (NH), 1732 (C=O), 1678 (C=O),  1566, 
1427 (C=N), 1087. ESI-TOF-MS: m/z for C19H27N3O2 [M+H]
+
: calcd 330.21760, found 
330.21713; m/z for C19H27N3O2 [M+Na]
+
: calcd 352.19955, found 352.20030; m/z for 
C19H27N3O2 [M+K]
+
: calcd 368.17349 found 368.17497.  
 
 (2a-E) from the mixture E/Z = 55:45. 
1
H-NMR (500 MHz, DMSO-d6): 0.71 (t, J = 10.5 Hz, 
1H, H-9), 0.84 (s, 3H, H3C-18), 0.97 (br.t, J = 9.5 Hz, 1H, Hα-7), 1.14‒1.30 (m, 4H, Hα-1, 
Hβ-11, Hα-12, H-14), 1.40‒1,54 (m, 2H, H-8, Hβ-15), 1.63 (br.d, J = 11 Hz, 1H, Hβ-12), 
1.75‒1.88 (m, 3H, Hβ-7, Hα-11, Hα-15), 1.90 (m, 1H, Hβ-2), 1.94‒2.29 (m, 4H, Hβ-1, Hα-6, 
H-10, Hα-16), 2.34‒2.43 (m, 2H, Hβ-6, Hβ-16), 2.68 (dt, J = 16.5, 4 Hz, 1H, Hα-2), 5.83 (s, 
1H, H-4), 6.20 (br.s, 2H, NH2), 9.11 (s, 1H, NH). 
13
C NMR (125 MHz, DMSO-d6): 219.7 (s, 
C-17), 157.3 (s, C=O), 148.5 (s, C-5), 147.2 (s, C-3), 121.9 (d, C-4), 49.5 (d, C-14), 49.0 (d, 
C-9), 47.1 (s, C-13), 40.7 (d, C-10), 39.2 (d, C-8), 35.3 (t, C-16), 34.1 (t, C-6), 31.2 (t, C-12), 
29.8 (t, C-7), 25.8 (t, C-1), 25.3 (t, C-11), 22.6 (t, C-2), 21.2 (t, C-15), 13.4 (q, C-18).   
 
(2a-Z) from the mixture E/Z = 55:45. 
1
H-NMR (500 MHz, DMSO-d6): 0.71 (t, J = 10.5 Hz, 
1H, H-9), 0.84 (s, 3H, H3C-18), 0.97 (br.t, J = 9.5 Hz, 1H, Hα-7), 1.14‒1.30 (m, 4H, Hα-1, 
Hβ-11, Hα-12, H-14), 1.40‒1,54 (m, 2H, H-8, Hβ-15), 1.63 (br.d, J = 11 Hz, 1H, Hβ-12), 
1.75‒1.88 (m, 3H, Hβ-7, Hα-11, Hα-15), 1.94‒2.29 (m, 6H, Hβ-1, Hα-2, Hβ-2, Hα-6, H-10, 
Hα-16), 2.34‒2.43 (m, 2H, Hβ-6, Hβ-16), 6.52 (s, 1H, H-4), 6.15 (br.s, 2H, NH2), 9.33 (s, 1H, 
NH). 
13
C NMR (125 MHz, DMSO-d6): 219.6 (s, C-17), 157.3 (s, C=O), 153.7 (s, C-5), 144.5 
(s, C-3), 112.9 (d, C-4), 49.4 (d, C-14), 49.3 (d, C-9), 47.1 (s, C-13), 42.1 (d, C-10), 39.3 (d, 
C-8), 35.3 (t, C-16), 34.9 (t, C-6), 31.1 (t, C-12), 30.0 (t, C-2), 30.0 (t, C-7), 27.3 (t, C-1), 25.1 
(t, C-11), 21.2 (t, C-15), 13.4 (q, C-18).   
 
Further elution with CH2Cl2/MeOH (100/12) gave  
2.1.1.2. 19-Norandrost-4-ene-3,17-dione bis(semicarbazone) (3a) (280 mg, 24.2%). Rf = 0.15 
(CH2Cl2/MeOH = 20:1). Mp > 200 °C (decomp.). IR (ATR/cm
-1
): 3461 and 3199 (NH), 2925, 
1688 (C=O), 1572, 1467, 1420 (C=N), 1088. ESI-TOF-MS: m/z for C20H30N6O2 [M+H]
+
: 
calcd 387.25030, found 387.24978; m/z for C20H30N6O2 [M+2H]
2+
: calcd 194.12879, found 
194.12894. 
  
 
(3a-E) from the mixture E/Z = 1:1. 
1
H-NMR (500 MHz, DMSO-d6): 0.75 (m, 1H, H-9), 0.85 
(s, 3H, H3C-18), 0.97 (td, J = 12.5, 3 Hz, 1H, Hα-7), 1.09, (m, 1H, H-14), 1.20‒1.29 (m, 3H, 
Hα-1, Hβ-11, Hα-12), 1.31‒1.43 (m, 2H, H-8, Hβ-15), 1.73‒1.88 (m, 5H, Hβ-1, Hβ-7, Hα-11, 
Hβ-12, Hα-15), 1.92 (m, 1H, Hβ-2), 1.96 (m, 1H, H-10), 2.11‒2.19 (m, 2H, Hα-6, Hα-16), 
2.33‒2.42 (m, 2H, Hβ-6, Hβ-16), 2.69 (dt, J = 16.5, 4 Hz, 1H, Hα-2), 5.83 (s, 1H, H-4), 6.09 
(br.s, 2H, NH2), 6.14 (br.s, 2H, NH2), 8.71 (s, 1H, NH), 9.06 (s, 1H, NH). 
13
C NMR (125 
MHz, DMSO-d6): 163.0 (s, C-17), 157.4 (s, C=O), 157.3 (s, C=O), 148.7 (s, C-5), 147.3 (s, 
C-3), 121.8 (d, C-4), 51.9 (d, C-14), 49.3 (d, C-9), 43.9 (s, C-13), 40.9 (d, C-10), 39.3 (d, C-
8), 34.2 (t, C-6), 33.9 (t, C-12), 30.6 (t, C-7), 26.2 (t, C-16), 25.9 (t, C-1), 25.7 (t, C-11), 22.9 
(t, C-15), 22.6 (t, C-2), 17.0 (q, C-18). 
 
 (3a-Z) from the mixture E/Z = 1:1. 
1
H-NMR (500 MHz, DMSO-d6): 0.75 (m, 1H, H-9), 0.85 
(s, 3H, H3C-18), 0.97 (td, J = 12.5, 3 Hz, 1H, Hα-7), 1.09, (m, 1H, H-14), 1.20‒1.29 (m, 3H, 
Hα-1, Hβ-11, Hα-12), 1.31‒1.43 (m, 2H, H-8, Hβ-15), 1.73‒1.88 (m, 5H, Hβ-1, Hβ-7, Hα-11, 
Hβ-12, Hα-15), 2.02 (m, 1H, H-10), 2.11‒2.19 (m, 2H, Hα-6, Hα-16), 2.21 (m, 1H, Hβ-2), 
2.33‒2.42 (m, 2H, Hβ-6, Hβ-16), 2.29 (dt, J = 14.5, 4 Hz, 1H, Hα-2), 6.09 (br.s, 2H, NH2), 
6.20 (br.s, 2H, NH2), 6.51 (s, 1H, H-4), 8.71 (s, 1H, NH), 9.29 (s, 1H, NH). 
13
C NMR (125 
MHz, DMSO-d6): 162.9 (s, C-17), 157.4 (s, C=O), 157.2 (s, C=O), 153.9 (s, C-5), 144.6 (s, 
C-3), 112.8 (d, C-4), 51.8 (d, C-14), 49.5 (d, C-9), 43.9 (s, C-13), 42.3 (d, C-10), 40.4 (d, C-
8), 35.0 (t, C-6), 33.8 (t, C-12), 30.4 (t, C-7), 30.1 (t, C-2), 27.3 (t, C-1), 26.2 (t, C-16), 25.5 
(t, C-11), 22.9 (t, C-15), 17.0 (q, C-18). 
 
2.1.1.3. Androst-4-ene-3,17-dione 3-semicarbazone (2b). The title compound was obtained 
starting from androst-4-ene-3,17-dione (1b) (860 mg). Elution with CH2Cl2/MeOH (100/2.5) 
gave 2b (520 mg, 50.5%). Rf = 0.30 (CH2Cl2/MeOH = 20:1). Mp > 205 °C (decomp.). IR 
(ATR/cm
-1
): 3448 and 3199 (NH), 2937, 1739 (C=O), 1682 (C=O),  1577, 1428 (C=N), 1088. 
ESI-TOF-MS: m/z for C20H29N3O2 [M+H]
+
: calcd 344.23325, found 344.23283.  
 
 (2b-E) from the mixture E/Z = 8:2.
 1
H-NMR (500 MHz, DMSO-d6): 0.81 (s, 3H, H3C-18), 
0.82 (m, 1H, H-9, overlapped with H3C-18), 0.93 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.01 (s, 3H, 
H3C-19), 1.15 (td, J = 12.5, 3.5 Hz, 1H, Hα-12), 1.21‒1.30 (m, 2H, Hα-1, H-14), 1.35 (m, 1H, 
Hβ-11), 1.49 (dtd, J = 3, 3.5, 3 Hz, 1H, Hβ-15), 1.57 (m, 1H, Hα-11), 1.61‒1.68 (m, 2H, Hβ-
1, Hβ-12), 1.79‒1.89 (m, 3H, Hβ-7, H-8, Hα-15), 1.92‒2.03 (m, 2H, Hβ-2 , Hα-16), 2.18 (dt, 
  
J = 12, 3.5 Hz, 1H, Hα-6), 2.31 (td, J = 14, 4.5 Hz, 1H, Hβ-6), 2.38 (dd, J = 19, 8.5 Hz, 1H, 
Hβ-16), 2.65 (dt, J = 17, 3 Hz, 1H, Hα-2), 5.73 (s, 1H, H-4), 6.19 (br.s, 2H, NH2), 9.06 (s, 1H, 
NH). 
13
C NMR (125 MHz, DMSO-d6): 219.6 (s, C-17), 157.2 (s, C=O), 152.8 (s, C-5), 146.8 
(s, C-3), 121.2 (d, C-4), 53.2 (d, C-9), 50.2 (d, C-14), 46.9 (s, C-13), 37.2 (s, C-10), 35.3 (d, 
C-16), 34.7 (d, C-8), 34.5 (t, C-1), 31.4 (t, C-6), 31.2 (t, C-12), 30.7 (t, C-7), 21.4 (t, C-15), 
20.4 (t, C-11), 20.3 (t, C-2), 17.5 (q, C-19), 13.4 (q, C-18).   
 
(2b-Z) from the mixture E/Z = 8:2.
 1
H-NMR (500 MHz, DMSO-d6): 0.81 (s, 3H, H3C-18), 
0.82 (m, 1H, H-9, overlapped with H3C-18), 0.93 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.07 (s, 3H, 
H3C-19), 1.15 (td, J = 12.5, 3.5 Hz, 1H, Hα-12), 1.25 (m, 1H, H-14), 1.31 (m, 1H, Hα-1), 1.49 
(dtd, J = 3, 3.5, 3 Hz, 1H, Hβ-15), 1.57 (m, 1H, Hβ-11), 1.61‒1.68 (m, 2H, Hβ-1, Hβ-12), 
1.79‒1.89 (m, 3H, Hβ-7, H-8, Hα-15), 1.92‒2.03 (m, 2H, Hα-11, Hα-16), 2.18 (dt, J = 12, 3.5 
Hz, 1H, Hα-6), 2.19 (m, 1H, Hβ-2), 2.33 (m, 1H, Hβ-6), 2.38 (dd, J = 19, 8.5 Hz, 1H, Hβ-16), 
2.29 (m, 1H, Hα-2), 6.12 (br.s, 2H, NH2), 6.43 (s, 1H, H-4), 9.30 (s, 1H, NH). 
13
C NMR (125 
MHz, DMSO-d6): 219.6 (s, C-17), 157.8 (s, C-5), 157.2 (s, C=O), 143.9 (s, C-3), 112.0 (d, C-
4), 53.5 (d, C-9), 50.1 (d, C-14), 46.9 (s, C-13), 38.3 (s, C-10), 36.1 (t, C-1), 35.3 (d, C-16), 
34.6 (d, C-8), 32.1 (t, C-6), 31.2 (t, C-12), 31.1 (t, C-7), 27.3 (t, C-2), 21.4 (t, C-15), 20.1 (t, 
C-11), 17.8 (q, C-19), 13.4 (q, C-18).   
 
Further elution with CH2Cl2/MeOH (100/12) gave  
2.1.1.4. Androst-4-ene-3,17-dione bis(semicarbazone) (3b) (162 mg, 13.5%). Rf = 0.15 
(CH2Cl2/MeOH = 20:1). Mp > 200 °C (decomp.). IR (ATR/cm
-1
): 3458 and 3320 (NH), 2937, 
1666 (C=O), 1573, 1475, 1426 (C=N), 1122, 1088. ESI-TOF-MS: m/z for C21H32N6O2 
[M+H]
+
: calcd 401.26595, found 401.26542; m/z for C21H32N6O2 [M+2H]
2+
: calcd 201.13661, 
found 201.13684. 
 
(3b-E) from the mixture E/Z = 55:45. 
1
H-NMR (500 MHz, CDCl3/CD3OD): 0.94 (s, 3H, H3C-
18), 0.95 (m, 1H, H-9, overlapped with H3C-18), 0.95 (td, J = 12.5, 4 Hz, 1H, Hα-7), 1.13 (s, 
3H, H3C-19), 1.18, (m, 1H, H-14, overlapped with H3C-19 from Z-isomer), 1.37 (m, 1H, Hα-
12), 1.43‒1.58 (m, 3H, Hα-1, Hβ-11, Hβ-15), 1.61‒1.75 (m, 2H, H-8, Hα-11), 1.85‒2.05 (m, 
4H, Hβ-1, Hβ-7, Hβ-12, Hα-15), 2.15 (m, 1H, Hβ-2), 2.22 (dd, J = 18.5, 9 Hz, 1H, Hα-16), 
2.29 (br.t, J = 2 Hz, 1H, Hα-6) 2.36 (br.t, J = 3 Hz, 1H, Hβ-6), 2.42 (dd, J = 18.5, 8.5 Hz, 1H, 
Hβ-16), 2.60 (dt, J = 16.5, 4 Hz, 1H, Hα-2), 5.83 (s, 1H, H-4). 13C NMR (125 MHz, 
CDCl3/CD3OD): 165.0 (s, C-17), 158.5 (s, C=O), 158.3 (s, C=O), 154.9 (s, C-5), 149.1 (s, C-
  
3), 120.3 (d, C-4), 53.5 (d, C-9), 52.7 (d, C-14), 43.8 (s, C-13), 37.3 (s, C-10), 34.8 (d, C-8), 
34.3 (t, C-1), 33.5 (t, C-12), 31.6 (t, C-6), 31.1 (t, C-7), 25.2 (t, C-16), 22.9 (t, C-15), 20.4 (t, 
C-11), 19.8 (t, C-2), 17.0 (q, C-19), 16.2 (q, C-18). 
 
(3b-Z) from the mixture E/Z = 55:45.
 1
H-NMR (500 MHz, CDCl3/CD3OD): 0.94 (s, 3H, H3C-
18), 0.95 (m, 1H, H-9, overlapped with H3C-18), 0.95 (td, J = 12.5, 4 Hz, 1H, Hα-7), 1.18 (s, 
3H, H3C-19), 1.18, (m, 1H, H-14, overlapped with H3C-19), 1.37 (m, 1H, Hα-12),  1.43‒1.58 
(m, 3H, Hα-1, Hβ-11, Hβ-15), 1.61‒1.75 (m, 2H, H-8, Hα-11), 1.85‒2.05 (m, 4H, Hβ-1, Hβ-
7, Hβ-12, Hα-15), 2.22 (dd, J = 18.5, 9 Hz, 1H, Hα-16), 2.32 (m, 1H, Hα-6), 2.36 (m, 1H, Hβ-
2, overlapped with Hβ-6 from E-isomer), 2.42 (dd, J = 18.5, 8.5 Hz, 1H, Hβ-16), 2.43 (m, 1H, 
Hα-2), 2.48 (m, 1H, Hβ-6), 6.15 (s, 1H, H-4). 13C NMR (125 MHz, CDCl3/ CD3OD): 164.8 
(s, C-17), 162.2 (s, C=O), 160.6 (s, C-5), 158.3 (s, C=O), 147.5 (s, C-3), 110.2 (d, C-4), 53.9 
(d, C-9), 52.6 (d, C-14), 43.9 (s, C-13), 38.6 (s, C-10), 36.0 (t, C-1), 34.7 (d, C-8), 33.4 (t, C-
12), 32.5 (t, C-6), 31.6 (t, C-7), 27.2 (t, C-2), 25.2 (t, C-16), 22.9 (t, C-15), 20.2 (t, C-11), 17.5 
(q, C-19), 16.3 (q, C-18). 
 
2.1.1.5. (E)-Androsta-4,9(11)-diene-3,17-dione 3-semicarbazone (2c). The title compound 
was obtained starting from androsta-4,9(11)-diene-3,17-dione (1c) (850 mg). Elution with 
CH2Cl2/MeOH (100/5) gave 2c as a pure E-isomer (780 mg, 76%). Rf = 0.30 (CH2Cl2/MeOH 
= 20:1). Mp > 205 °C (decomp.). IR (ATR/cm
-1
): 3427 and 3211 (NH), 2927, 1734 (C=O), 
1686 (C=O),  1592, 1473 (C=N), 1089. 
1
H-NMR (500 MHz, DMSO-d6): 0.78 (s, 3H, H3C-
18), 0.96 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.18 (s, 3H, H3C-19), 1.50 (m, H-14), 1.56 (dtd, J = 
3, 3.5, 3 Hz, 1H, Hβ-15), 1.68 (td, J = 13.5, 4.5 Hz, 1H, Hα-12), 1.90 (m, 1H, Hα-1), 
1.98‒2.05 (m, 4H, Hβ-1, Hβ-7, Hβ-12, Hα-15), 2.06‒2.17  (m, 2H, Hβ-2, Hα-16), 2.26 (dt, J 
= 11.5, 3 Hz, 1H, Hα-6), 2.34 (br.t, J = 11 Hz, 1H, H-8), 2.40 (dd, J = 18.5, 8.5 Hz, 1H, Hβ-
16), 2.50 (m, 1H, Hβ-6), 2.73 (dt, J = 17, 3.5 Hz, 1H, Hα-2), 5.48 (d, J = 6 Hz, 1H, H-11), 
5.74 (s, 1H, H-4), 6.24 (bs, 2H, NH2), 9.18 (s, 1H, NH). 
13
C NMR (125 MHz, DMSO-d6): 
220.3 (s, C-17), 157.2 (s, C=O), 151.1 (s, C-5), 146.6 (s, C-3), 146.3 (s, C-9), 121.3 (d, C-4), 
116.3 (d, C-11),  47.3 (d, C-14), 45.2 (s, C-13), 39.8 (s, C-10), 36.6 (d, C-8), 35.8 (d, C-16), 
33.1 (t, C-1), 32.7 (t, C-12), 31.4 (t, C-6), 31.1(t, C-7), 26.3 (q, C-19), 22.3 (t, C-15), 20.8 (t, 
C-2), 13.6 (q, C-18).  ESI-TOF-MS: m/z for C20H27N3O2 [M+H]
+
: calcd 342.21760, found 
342.21731;  m/z for C20H27N3O2 [M+Na]
+
: calcd 364.19955, found 364.20002. 
 
Further elution with CH2Cl2/MeOH (100/20) gave  
  
2.1.1.6. Androsta-4,9(11)-diene-3,17-dione bis(semicarbazone) (3c). Yield (120 mg, 10%). Rf 
= 0.15 (CH2Cl2/MeOH = 20:1). Mp > 200 °C (decomp.). IR (ATR/cm
-1
): 3463 and 3202 
(NH), 1685(C=O), 1581, 1473, 1428 (C=N), 1089. ESI-TOF-MS: m/z for C21H30N6O2 
[M+H]
+
: calcd 399.25030, found 399.24961; m/z for C21H30N6O2 [M+2H]
2+
: calcd 200.12879, 
found 200.12900; m/z for C21H30N6O2 [M+Na]
+
: calcd 421.23225, found 421.23209. 
 
(3c-E) from the mixture E/Z = 85:15. 
1
H-NMR (500 MHz, DMSO-d6): 0.79 (s, 3H, H3C-18), 
0.96 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.17 (s, 3H, H3C-19), 1.26 (m, H-14), 1.43 (dtd, J = 3, 3,  
3 Hz, 1H, Hβ-15), 1.68 (td, J = 13.5, 5 Hz, 1H, Hα-1), 1.88‒2.02 (m, 3H, Hβ-1, Hβ-7, Hα-
15), 2.06‒2.13  (m, 3H, Hβ-2, Hα-12, Hβ-12), 2.18 (dd, J = 19, 9.5 Hz, 1H, Hα-16), 2.21 (m, 
1H, H-8), 2.24 (dt, J = 18, 3 Hz, 1H, Hα-6), 2.44 (dd, J = 18.5, 9 Hz, 1H, Hβ-16), 2.48 (m, 
1H, Hβ-6), 2.74 (dt, J = 17, 3.5 Hz, 1H, Hα-2), 5.48 (d, J = 5 Hz, 1H, H-11), 5.75 (s, 1H, H-
4), 6.14 (br.s, 2H, NH2), 6.24 (s, 2H, NH2), 8.81 (s, 1H, NH), 9.15 (s, 1H, NH). 
13
C NMR 
(125 MHz, DMSO-d6): 162.6 (s, C-17), 157.4 (s, C=O), 157.3 (s, C=O), 151.4 (s, C-5), 146.6 
(s, C-3), 146.1 (s, C-9), 121.3 (d, C-4), 117.0 (d, C-11),  49.7 (d, C-14), 42.2 (s, C-13), 39.7 
(s, C-10, overlapped with DMSO), 36.4 (t, C-8), 36.2 (d, C-12), 32.6 (t, C-1), 31.7 (t, C-6), 
31.5(t, C-7), 26.6 (t, C-16), 26.2 (q, C-19), 24.0 (t, C-15), 20.8 (t, C-2), 17.1 (q, C-18).   
 
(3c-Z) from the mixture E/Z = 85:15. 
1
H-NMR (500 MHz, DMSO-d6): 0.79 (s, 3H, H3C-18), 
0.96 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.23 (s, 3H, H3C-19), 1.26 (m, H-14), 1.43 (dtd, J = 3, 3, 
3 Hz, 1H, Hβ-15), 1.79 (td, J = 13.5, 3.5 Hz, 1H, Hα-1), 1.88‒2.02 (m, 3H, Hβ-1, Hβ-7, Hα-
15), 2.06‒2.10  (m, 1H, Hα-12, Hβ-12), 2.18 (dd, J = 19, 9.5 Hz, 1H, Hα-16), 2.21 (m, 1H, H-
8), 2.24 (dt, J = 18, 3 Hz, 1H, Hα-6), 2.32 (t, J = 3.5 Hz, 1H, Hβ-2), 2.38 (m, 1H, Hα-2), 2.44 
(dd, J = 18.5, 9 Hz, 1H, Hβ-16), 2.48 (m, 1H, Hβ-6), 5.48 (d, J = 5 Hz, 1H, H-11), 6.14 (br.s, 
2H, NH2), 6.18 (s, 2H, NH2), 6.45 (s, 1H, H-4), 8.81 (s, 1H, NH), 9.35 (s, 1H, NH). 
13
C NMR 
(125 MHz, DMSO-d6): 162.6 (s, C-17), 157.4 (s, C=O), 157.3 (s, C=O), 156.4 (s, C-5), 146.1 
(s, C-9), 144.2 (s, C-3), 117.0 (d, C-11),  112.3 (d, C-4), 49.7 (d, C-14), 42.2 (s, C-13), 41.0 
(s, C-10, overlapped with DMSO), 36.4 (t, C-8), 36.2 (d, C-12), 34.4 (t, C-1), 32.1 (t, C-6), 
31.5 (t, C-7), 27.6 (t, C-2), 26.6 (t, C-16), 26.6 (q, C-19), 24.0 (t, C-15), 17.1 (q, C-18).   
 
2.1.1.7. 11α-Hydroxyandrost-4-ene-3,17-dione 3-semicarbazone (2d). The title compound 
was obtained starting from androst-4-ene-11α-ol-3,17-dione (1d) (910 mg). Elution with 
CH2Cl2/MeOH (100/5) gave 2d (163 mg, 15.1%). Rf = 0.53  (CH2Cl2/MeOH = 20:2). Mp > 
218 °C (decomp.). IR (ATR/cm
-1
): 3456 (OH), 3209 (NH), 2929, 1731 (C(17)=O), 1689 
  
(C=O), 1572 and 1458, (C=N), 1087, 730. HESI-Orbitrap MS: m/z for C20H29N3O3 [M+H]
+
: 
calcd 360.2282, found 360.2264 
 
(2d-E) from the mixture E/Z = 80:20. 
1
H-NMR (200 MHz, CDCl3): 0.93 (s, 3H, H3C-18), 
1.00‒1.15 (m, 2H, Hα-7, H-9), 1.21 (s, 3H, H3C-19),  1.26‒1.49 (m, 2H), 1.52‒1.75 (m, 3H), 
1.81‒2.36 (m, 9H), 2.40‒2.59 (m, 2H) 2.66 (dt, J = 14, 3.2 Hz, 1H, Hα-1), 4.01 (td, J = 10.8, 
4.6 Hz, 1H, Hβ-11),  5.83 (s, 1H, H-4), 8.31 (s, 1H, NH). 13C NMR (50 MHz, CDCl3): 219.0 
(s, C-17), 157.9 (s, C=O), 155.0 (s, C-5), 148.8 (s, C-3), 121.7 (d, C-4), 68.7 (d, C-11), 59.1 
(d, C-9), 50.1 (d, C-14), 48.0 (s, C-13), 48.0 (t, C-12), 39.0 (s, C-10), 35.8 (t, C-16), 34.7 (d, 
C-8), 34.5 (t, C-1), 32.8 (t, C-6), 30.3 (t, C-7), 21.6 (t, C-15), 20.6 (t, C-2), 18.5 (q, C-19), 
14.6 (q, C-18).   
 
(2d-Z) from the mixture E/Z = 80:20. 
1
H-NMR (200 MHz, CDCl3): 0.93 (s, 3H, H3C-18), 
1.00‒1.15 (m, 2H, Hα-7, H-9), 1.26 (s, 3H, H3C-19), 1.26‒1.49 (m, 2H), 1.52‒1.75 (m, 3H), 
1.81‒2.36 (m,9H), 2.40‒2.59 (m, 3H), 4.01 (td, J = 10.8, 4.6 Hz, 1H, Hβ-11),  6.15 (s, 1H, H-
C(4)), 8.09 (s, 1H, NH). 
13
C NMR (50 MHz, CDCl3): 219.0 (s, C-17), 157.9 (s, C=O), 155.0 
(s, C-5), 148.8 (s, C-3), 111.8 (d, C-4), 68.7 (d, C-11), 59.1 (d, C-9), 50.1 (d, C-14), 48.0 (s, 
C-13), 48.0 (t, C-12), 39.0 (s, C-10), 35.8 (t, C-16), 34.7 (d, C-8), 34.5 (t, C-1), 32.8 (t, C-6), 
30.3 (t, C-7), 27.7 (t, C-2), 21.6 (t, C-15), 18.5 (q, C-19), 14.6 (q, C-18).   
 
Further elution with the same eluent gave  
2.1.1.8. (E)-11α-Hydroxyandrost-4-ene-3,17-dione 17-semicarbazone (4d) as a pure E-isomer 
(147 mg, 13.6%). Rf = 0.44 (CH2Cl2/MeOH = 20:2). Mp > 215 °C (decomp.). IR (ATR/cm
-1
): 
3456 (OH), 3196 (NH), 2940, 1695  (C=O), 1638 (C(3)=O), 1576 and 1415, (C=N), 1083. 
1
H-NMR (500 MHz, DMSO-d6): 0.83 (s, 3H, H3C-18), 1.01 (qd, J = 13, 3 Hz, 1H, Hα-7), 
1.06 (t, J = 11.5 Hz, 1H, H-9), 1.13 (m, 1H, H-14), 1.25 (s, 3H, H3C-19), 1.26 (m, 1H, Hα-12, 
overlapped with H3C-19), 1.35 (dtd, J = 3, 2.5, 3 Hz, 1H, Hβ-15), 1.60 (qd, J = 11, 3 Hz, 1H, 
H-8), 1.75 (m, 1H, Hα-15), 1.82 (br.d, J = 12.5 Hz, 1H, Hβ-7), 1.93 (td, J = 14, 4.5 Hz, 1H, 
Hβ-2), 2.09 (dd, J = 12, 4 Hz, 1H, Hβ-12), 2.14 (t, J = 4 Hz, 1H, Hα-1), 2.17‒2.26 (m, 2H, 
Hα-6, Hα-16), 2.28‒2.44 (m, 3H, Hβ-6, Hβ-16, Hβ-1), 2.58 (dt, J = 14.5, 4 Hz, 1H, Hα-2), 
3.85 (m, 1H, Hβ-11), 4.35 (d, J = 7.5 Hz, 1H,OH-11), 5.61 (s, 1H, H-4), 6.08 (bs, 2H, NH2), 
8.73 (s, 1H, NH).
13
C NMR (125 MHz, DMSO-d6): 198.6 (s, C-3), 171.5 (s, C-5), 162.1 (s, C-
17), 157.3 (s, C=O), 123.6 (d, C-4), 67.2 (d, C-11), 58.6 (d, C-9), 51.9 (d, C-14), 45.1 (t, C-
12), 44.2 (s, C-13), 39.5 (s, C-10), 36.9 (t, C-2), 33.9 (t, C-1), 33.8 (d, C-8), 32.8 (t, C-6), 30.9 
  
(t, C-7), 26.3 (t, C-16), 22.9 (t, C-15), 18.0 (q, C-19), 17.9 (q, C-18). HESI-Orbitrap MS: m/z 
for C10H29N3O3 [M+H]
+
: calcd 360.2282, found 360.2264.  
 
Further elution with CH2Cl2/MeOH (100/30) gave  
2.1.1.9. (E)-11α-Hydroxyandrost-4-ene-3,17-dione bis(semicarbazone) (3d) as a pure E-
isomer (215 mg, 17.2%). Rf = 0.21 (CH2Cl2/MeOH = 20:2). Mp > 223 °C (decomp.). IR 
(ATR/cm
-1
): 3457 (OH), 3284 (NH), 2927, 1681 (C=O), 1571 and 1420, (C=N), 1082. 
1
H-
NMR (200 MHz, CDCl3/CD3OD): 0.76 (s, 3H, H3C-18), 0.85‒0.99 (m, 2H, Hα-7, H-9), 1.05 
(s, 3H, H3C-19), 1.16‒1.29 (m, 2H), 1.35‒1.55 (m, 2H), 1.60‒1.86 (m, 3H), 1.93‒(2.29 (m, 
6H), 2.32‒2.56 (m, 3H), 3.83 (m, 1H, Hβ-11), 5.65 (s, 1H, H-4), 8.10 (s, 1H, NH), 8.39 (s, 
1H, NH). 
13
C NMR (50 MHz, CDCl3/CD3OD): 163.9 (s, C-17), 158.6 (s, C=O), 158.5 (s, 
C=O), 155.7 (s, C-5), 149.6 (s, C-3), 121.1 (d, C-4), 68.1 (d, C-11), 58.6 (d, C-9), 51.8 (d, C-
14), 44.6 (t, C-12), 44.3 (s, C-13), 38.7 (s, C-10), 35.6 (d, C-8), 34.4 (t, C-1), 32.7 (t, C-6), 
30.9 (t, C-7), 25.6 (t, C-16), 23.0 (t, C-15), 20.3 (t, C-2), 18.1 (q, C-19), 17.4 (q, C-18). HESI-
Orbitrap MS: m/z for C21H32N6O6 [M+H]
+
: calcd 417.2609, found 417.2626. 
 
2.1.1.10. Progesterone 3-semicarbazone (2e). The title compound was obtained starting from 
progesterone (1e) (940 mg). Elution with CH2Cl2/MeOH (100/4) gave 2e (480 mg, 43.1%). Rf 
= 0.30  (CH2Cl2/MeOH = 20:1). Mp > 200 °C (decomp.). IR (ATR/cm
-1
): 3473 and 3310 
(NH), 2930, 1696 (C=O), 1676 (C=O), 1577, 1428 (C=N), 1358, 757. ESI-TOF-MS: m/z for 
C22H33N3O2 [M+H]
+
: calcd 372.26455, found 372.26441; m/z for C22H33N3O2 [M+Na]
+
: calcd 
394.24650, found 394.24726. 
 
(2e-E) from the mixture E/Z = 90:10. 
1
H-NMR (500 MHz, DMSO-d6): 0.56 (s, 3H, H3C-18), 
0.83 (td, J = 12, 3.5 Hz, 1H, H-9), 0.90 (qd, J = 13.5, 3.5 Hz, 1H, Hα-7), 1.01 (s, 3H, H3C-
19), 1.11‒1.20 (m, 2H, H-14, Hα-16), 1.25‒1.51 (m, 4H, Hα-1, H-8, Hβ-11, Hα-12), 
1.53‒1.59 (m, 2H, Hα-11, Hβ-15), 1.63 (m, 1H, Hβ-16), 1.72 (br.d, J = 12.5 Hz, 1H, Hβ-7), 
1.88 (m, 1H, Hβ-1), 1.94‒2.05 (m, 3H, Hβ-2, Hβ-12, Hα-15), 2.06 (s, 3H, H3C-21),  2.16 (dt, 
J = 13.5, 3 Hz, 1H, Hα-6), 2.29 (td, J = 12.5, 3 Hz, 1H, Hβ-6), 2.57 (t, J = 9 Hz, 1H, H-17), 
2.68 (dt, J = 17, 3 Hz, 1H, Hα-2), 5.73 (s, 1H, H-4), 6.21 (m, 2H, NH2), 9.08 (s, 1H, NH). 
13
C 
NMR (50 MHz, DMSO-d6): 208.6 (s, C-20), 157.2 (s, C=O), 153.0 (s, C-5), 146.8 (s, C-3), 
121.1 (d, C-4), 62.6 (d, C-17), 55.5 (d, C-14), 53.0 (d, C-9), 43.3 (s, C-13), 38.0 (t, C-12), 
37.1 (s, C-10), 35.2 (d, C-8), 34.5 (t, C-1), 31.9 (t, C-7), 31.6 (t, C-6), 31.2 (q, C-21), 24.0 (t, 
C-16), 22.2 (t, C-15), 21.0 (t, C-11), 20.4 (t, C-2), 17.5 (q, C-19), 13.1 (q, C-18).  
  
(2e-Z) from the mixture E/Z = 90:10. 
1
H-NMR (500 MHz, DMSO-d6): 0.56 (s, 3H, H3C-18), 
0.83 (td, J = 12, 3.5 Hz, 1H, H-9), 0.90 (qd, J = 13.5, 3.5 Hz, 1H, Hα-7), 1.06 (s, 3H, H3C-
19), 1.11‒1.20 (m, 2H, H-14, Hα-16), 1.25‒1.51 (m, 4H, Hα-1, H-8, Hβ-11, Hα-12), 
1.53‒1.59 (m, 2H, Hα-11, Hβ-15), 1.63 (m, 1H, Hβ-16), 1.72 (br.d, J = 12.5 Hz, 1H, Hβ-7), 
1.88 (m, 1H, Hβ-1), 1.94‒2.05 (m, 2H, Hβ-12, Hα-15), 2.06 (s, 3H, H3C-21),  2.16 (dt, J = 
13.5, 3 Hz, 1H, Hα-6), 2.23 (m, 1H, Hβ-2), 2.29 (td, J = 12.5, 3 Hz, 1H, Hβ-6), 2.57 (t, J = 9 
Hz, 1H, H-17), 2.35 (m, 1H, Hα-2), 6.14 (m, 2H, NH2), 6.43 (s, 1H, H-4), 9.32 (s, 1H, NH). 
13
C NMR (50 MHz, DMSO-d6): 208.6 (s, C-20), 158.1 (s, C-5), 157.2 (s, C=O), 144.2 (s, C-
3), 111.9 (d, C-4), 62.6 (d, C-17), 56.1 (d, C-14), 53.2 (d, C-9), 43.3 (s, C-13), 38.2 (s, C-10), 
38.0 (t, C-12), 36.2 (t, C-1), 35.1 (d, C-8), 32.3 (t, C-7), 32.2 (t, C-6), 31.2 (q, C-21), 27.4 (t, 
C-2), 24.0 (t, C-16), 22.2 (t, C-15), 20.8 (t, C-11), 17.8 (q, C-19), 13.1 (q, C-18). 
Further elution with CH2Cl2/MeOH (100/15) gave 
2.1.1.11. (E)-Pregn-4-ene-3,20-dione bis(semicarbazone) 3e as a pure E-isomer (128 mg, 
10.2%). Rf = 0.18 (CH2Cl2/MeOH = 20:2). Mp > 220 °C (decomp.). IR (ATR/cm
-1
): 3453, 
3189 (NH), 2937, 1687 (C=O), 1570, 1437 (C=N), 1116, 766. 
1
H-NMR (500 MHz, DMSO-
d6): 0.55 (s, 3H, H3C-18), 0.81 (m, 1H, H-9), 0.89 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.00 (s, 3H, 
H3C-19), 1.08‒1.21 (m, 2H, H-14, Hα-15), 1.23‒1.36 (m, 3H, Hα-1, Hβ-11, Hβ-12), 1.44 (qd, 
J = 10.5, 2 Hz, 1H, H-8), 1.50‒1.58 (m, 2H, Hα-11, Hα-16), 1.61 (m, 1H, Hβ-15), 1.73 (m, 
1H, Hβ-7), 1.76 (s, 3H, H3C-21), 1.80 (m, 1H, Hα-12), 1.87 (br.d, J = 13 Hz, 1H, Hβ-1), 1.97 
(dtd, J = 5, 5, 4.5 Hz, 1H, Hβ-2), 2.15 (dt, J = 13.5, 2.5 Hz, 1H, Hα-6), 2.19‒2.25 (m, 2H, Hβ-
16, Hα-17), 2.29 (td, J = 13.5, 4 Hz, 1H, Hβ-6), 2.67 (dt, J = 17, 3 Hz, 1H, Hα-2), 5.72 (s, 1H, 
H-4), 6.14 (br.s, 2H, NH2), 6.20 (s, 2H, NH2), 8.78 (s, 1H, NH), 9.06 (s, 1H, NH). 
13
C NMR 
(125 MHz, DMSO-d6): 157.4 (s, C=O), 157.1 (s, C=O), 153.0 (s, C-5), 148.8 (s, C-20), 146.8 
(s, C-3), 120.9 (d, C-4), 58.2 (d, C-17), 55.2 (d, C-14), 53.3 (d, C-9), 43.3 (s, C-13), 38.2 (t, 
C-12), 37.0 (s, C-10), 35.4 (d, C-8), 34.5 (t, C-1), 31.9 (t, C-6), 31.6 (t, C-7), 23.8 (t, C-15), 
22.7 (t, C-16), 21.0 (t, C-11), 20.4 (t, C-2), 17.6 (q, C-21), 17.5 (q, C-19), 13.1 (q, C-18). ESI-
TOF-MS: m/z for C23H36N6O2 [M+H]
+
: calcd 429.29725, found 429.29678; m/z for 
C22H33N3O2 [M+Na]
+
: calcd 451.27920, found 451.27953. 
 
2.1.2. Synthesis of ethyl hydrazinecarboxilates  
Into a solution of steroidal semicarbazones (2a‒e, 1 mmol) and anhydrous sodium 
acetate (123 mg, 1.5 mmol) in absolute ethanol (30 mL), ethyl chloroacetate (244 mg, 2 
mmol) was slowly added. The mixture was heated under reflux until the reaction was 
completed (for 48‒96 h, monitored by TLC), allowed to attain room temperature and then 
  
poured into ice water. The resulting solution was extracted with chloroform (three times), and 
dried over sodium sulfate. Evaporation of the solvent afforded a solid which was purified by 
column chromatography, using toluene/EtOAc as eluent (yield, and the ratio of eluents 
mentioned in each experiment). 
 
2.1.2.1. Ethyl (17-oxo-19-norandrost-4-en-3-ylidene)hydrazinecarboxylate (5a). The title 
compound was obtained starting from (E)-19-norandrost-4-ene-3,17-dione 3-semicarbazone 
2a (330 mg). Elution with PhMe/EtOAc (7/3) gave compound 5a  (E/Z = 55:45) (114 mg, 
31.7%). Rf = 0.67 (CH2Cl2/MeOH = 20:1). Mp > 160 °C (decomp.). IR (ATR/cm
-1
): 3232 and 
2928 (NH), 1737 (C=O), 1686 (C=O),  1424 (C=N), 1300, 1057. Anal. calcd for C21H30N2O3: 
C 70.36; H 8.44;  N 7.81; Found: C 69.87; H 8.10;  N 7.44. 
 
(5a-E) from the mixture E/Z = 6:4. 
1
H-NMR (500 MHz, CDCl3): 0.80 (m, 1H, H-9), 0.92 (s, 
3H, H3C-18), 1.07 (td, J = 12.5, 3.5 Hz, 1H, Hα-7), 1.22‒1.36 (m, 7H, Hα-1, Hβ-11, Hβ-12, 
H-14, CH3CH2), 1.45 (m, 1H, H-8), 1.56 (td, J = 9, 3.5 Hz, 1H, Hβ-15), 1.83 (m, 1H, Hα-12), 
1.86‒2.00 (m, 5H, Hβ-2, Hβ-7, H-10, Hα-11, Hα-15), 2.10 (dd, J = 19, 9 Hz, 1H, Hα-16), 
2.14‒2.22 (m, 2H, Hβ-1, Hα-6), 2.38‒2.50 (m, 2H, Hβ-6, Hβ-16), 2.56 (dt, J = 15.5, 3.5 Hz, 
1H, Hα-2), 4.28 (br.d, J = 5 Hz, 2H, CH3CH2), 6.09 (s, 1H, H-4), 7.86 (s, 1H, NH). 
13
C NMR 
(125 MHz, CDCl3): 220.9 (s, C-17), 154.2 (s, C=O), 151.5 (s, C-3), 150.3 (s, C-5), 122.2 (d, 
C-4), 61.9 (t, CH3CH2), 50.3 (d, C-14), 49.5 (d, C-9), 47.8 (s, C-13), 41.5 (d, C-10), 40.0 (d, 
C-8), 35.8 (t, C-16), 34.7 (t, C-6), 31.4 (t, C-12), 30.1 (t, C-7), 26.0 (t, C-1), 25.9 (t, C-11), 
22.2 (t, C-2), 21.7 (t, C-15), 14.6 (q, CH3CH2), 13.8 (q, C-18).  
 
(5a-E) from the mixture E/Z = 6:4. 
1
H-NMR (500 MHz, DMSO-d6): 0.71 (td, J = 13, 2.5 Hz, 
1H, H-9), 0.84 (s, 3H, H3C-18), 0.96 (td, J = 11.5, 2.5 Hz, 1H, Hα-7), 1.14 (br.s, 1H, Hα-1), 
1.17 (m, 1H,  Hβ-12), 1.18‒1.23 (m, 4H, Hβ-11, CH3CH2), 1.28 (m, 1H, H-14), 1.44 (br.d, J 
= 11.5 Hz,1H, H-8), 1.50 (dtd, J = 2.5 Hz, 1H, Hβ-15), 1.63 (d, J = 11 Hz, 1H, Hα-12), 
1.75‒1.88 (m, 3H, Hβ-7, Hα-11, Hα-15), 1.92 (dt, J = 17.5, 3.5 Hz, 1H, Hβ-2), 1.95‒2.09 (m, 
3H, Hβ-1, H-10, Hα-16), 2.18 (m, 1H, Hα-6), 2.34‒2.44 (m, 2H, Hβ-6, Hβ-16), 2.71 (dt, J = 
17, 4 Hz, 1H, Hα-2), 4.09 (q, J = 7Hz, 2H, CH3CH2), 5.86 (s, 1H, H-4), 9.78 (s, 1H, NH). 
13
C 
NMR (125 MHz, DMSO-d6): 220.4 (s, C-17), 154.1(s, C=O), 151.8 (s, C-3), 149.9 (s, C-5), 
121.7 (d, C-4), 60.2 (t, CH3CH2), 49.5 (d, C-14), 49.0 (d, C-9), 47.1 (s, C-13), 40.8 (d, C-10), 
39.2 (d, C-8), 35.3 (t, C-16), 34.1 (t, C-6), 31.2 (t, C-12), 29.7 (t, C-7), 27.1 (t, C-1), 25.9 (t, 
C-11), 23.0 (t, C-2), 21.3 (t, C-15), 14.6 (q, CH3CH2), 13.4 (q, C-18).  
  
 
(5a-Z) from the mixture E/Z = 6:4. 
1
H-NMR (500 MHz, CDCl3): 0.80 (m, 1H, H-9), 0.92 (s, 
3H, H3C-18), 1.07 (td, J = 12.5, 3.5 Hz, 1H, Hα-7), 1.22‒1.36 (m, 8H, Hα-1, H-8, Hβ-11, Hβ-
12, H-14, CH3CH2), 1.57 (dtd, J = 3.5 Hz, 1H, Hβ-15), 1.83 (m, 1H, Hα-12),  1.86‒2.00 (m, 
3H, Hβ-7, Hα-11, Hα-15), 2.03  (m, 1H, H-10), 2.10 (dd, J = 19, 9 Hz, 1H, Hα-16), 2.16 (m, 
1H, Hβ-1), 2.27 (td, J = 14, 4 Hz, 2H, Hβ-2, Hα-6), 2.38‒2.50 (m, 2H, Hβ-6, Hβ-16), 2.56 (dt, 
J = 15.5, 3.5 Hz, 1H, Hα-2), 4.28 (br.d, J = 5 Hz, 2H, CH3CH2), 6.12 (s, 1H, H-4), 8.05 (br.s, 
1H, NH). 
13
C NMR (125 MHz, CDCl3): 220.6 (s, C-17), 156.7 (s, C-3), 154.2 (s, C=O), 150.5 
(s, C-5), 111.1 (d, C-4), 61.9 (t, CH3CH2), 50.2 (d, C-14), 50.0 (d, C-9), 47.8 (s, C-13), 43.3 
(d, C-10), 40.2 (d, C-8), 35.9 (t, C-6), 35.8 (t, C-16), 31.3 (t, C-12), 30.5 (t, C-2), 30.5 (t, C-
7), 27.4 (t, C-1), 25.6 (t, C-11), 21.7 (t, C-15), 14.6 (q, CH3CH2), 13.8 (q, C-18).  
 
(5a-Z) from the mixture E/Z = 6:4. 
1
H-NMR (500 MHz, DMSO-d6): 0.71 (td, J = 13, 2.5 Hz, 
1H, H-9), 0.84 (s, 3H, H3C-18), 0.96 (td, J = 11.5, 2.5 Hz, 1H, Hα-7), 1.17 (m, 1H,  Hβ-12), 
1.18‒1.23 (m, 6H, Hα-1, H-8, Hβ-11, CH3CH2), 1.49 (m, 1H, H-14), 1.50 (dtd, J = 2.5 Hz, 
1H, Hβ-15), 1.63 (d, J = 11 Hz, 1H, Hα-12), 1.75‒1.88 (m, 3H, Hβ-7, Hα-11, Hα-15), 
1.95‒2.09 (m, 3H, Hβ-1, H-10, Hα-16), 2.18 (m, 2H, Hβ-2, Hα-6), 2.29 (dt, J = 14.5, 4 Hz, 
1H, Hα-2), 2.34‒2.44 (m, 2H, Hβ-6, Hβ-16), 4.09 (q, J = 7 Hz, 2H, CH3CH2), 6.51 (s, 1H, H-
4), 9.98 (s, 1H, NH). 
13
C NMR (125 MHz, DMSO-d6): 220.3 (s, C-17), 154.1 (s, C=O), 154.4 
(s, C-3), 148.9 (s, C-5), 112.9 (d, C-4), 60.1 (t, CH3CH2), 49.4 (d, C-14), 49.3 (d, C-9), 47.1 
(s, C-13), 42.1 (d, C-10), 39.2 (d, C-8), 35.3 (t, C-16), 34.9 (t, C-6), 31.1 (t, C-12), 30.0 (t, C-
2), 29.9 (t, C-7), 27.1 (t, C-1), 25.1 (t, C-11), 21.3 (t, C-15), 14.6 (q, CH3CH2), 13.4 (q, C-18).  
 
2.1.2.2. Ethyl (17-oxoandrost-4-en-3-ylidene-hydrazinecarboxylate (5b). The title compound 
was obtained starting from androst-4-ene-3,17-dione 3-semicarbazone (2b) (E/Z = 8:2) (340 
mg). Elution with PhMe/EtOAc (6/4) gave 5b (E/Z = 9:1), (185.5 mg, 49.8%). Rf = 0.39 
(PhMe:EtOAc = 6:4, double devolopment). Crystallization from the mixture CH2Cl2/CH3OH 
did not yield crystals suitable for X-ray analysis. Mp = 121.6‒123.9 °C. IR (ATR/cm-1): 3232 
(NH), 2928, 2864, 1737 (C=O), 1687, 1424, 1300 (C=N), 1057. Anal. calcd for C22H32N2O3 × 
0.5 CH2Cl2 × 0.2 C7H8: C 66.45; H 8.06; N 6.40;  Found: C 66.11; H 8.04; N 6.23. 
 
(5b-E) from the mixture E/Z = 8:2.
 1
H-NMR (500 MHz, CDCl3): 0.90 (s, 3H, H3C-18), 0.91 
(m, 1H, H-9, overlapped with H3C-18), 1.03 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.08 (s, 3H, H3C-
19), 1.24‒1.29 (m, 2H, Hα-12, H-14), 1.31 (t, J = 7.5 Hz, 3H, CH3CH2), 1.40‒1.48 (m, 2H, 
  
Hα-1, Hα-11), 1.54 (dtd, J = 2, 2, 2 Hz, 1H, Hβ-15), 1,65‒1.70 (m, 2H, H-8, Hβ-11), 1.84 (d, 
J = 12.5 Hz, 1H, Hβ-12), 1.89 (m, 1H, Hβ-7), 1.94‒2.02 (m, 2H, Hβ-1, Hα-15), 2.04‒2.12 (m, 
2H, Hβ-2, Hα-16), 2.20‒2.33 (m, 2H, Hα-6, Hβ-6), 2.46 (dd, J = 19.5, 9 Hz, 1H, Hβ-16), 2.54 
(br.d, J = 16 Hz, 1H, Hα-2), 4.28 (br.d, J = 5 Hz, 2H, CH3CH2), 6.00 (s, 1H, H-4), 7.83 (br.s, 
1H, NH). 
13
C NMR (125 MHz, CDCl3): 220.8 (s, C-17), 154.9 (s, C-5), 154.3 (s, C=O), 150.9 
(s, C-3), 121.3 (d, C-4), 61.9 (t, CH3CH2), 53.6 (d, C-9), 51.0 (d, C-14), 47.5 (s, C-13), 37.7 
(s, C-10), 35.8 (d, C-16), 35.4 (t, C-8), 34.7 (t, C-1), 32.0 (t, C-6), 31.4 (t, C-12), 30.9 (t, C-7), 
21.8 (t, C-15), 20.7 (t, C-11), 20.1 (t, C-2), 17.8 (q, C-19), 14.6 (q, CH3CH2), 13.7 (q, C-18).   
 
(5b-Z) from the mixture E/Z = 8:2.
 1
H-NMR (500 MHz, CDCl3): 0.90 (s, 3H, H3C-18), 0.91 
(m, 1H, H-9, overlapped with H3C-18), 1.03 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.14 (s, 3H, H3C-
19), 1.24‒1.29 (m, 2H, Hα-12, H-14), 1.31 (t, J = 7.5 Hz, 3H, CH3CH2), 1.40‒1.48 (m, 2H, 
Hα-1, Hα-11), 1.54 (dtd, J = 2, 2, 2 Hz, 1H, Hβ-15), 1.65‒1.70 (m, 2H, H-8, Hβ-11), 1.84 (d, 
J = 12.5 Hz, 1H, Hβ-12), 1.88‒1.93 (m, 2H, Hβ-1, Hβ-7), 1.98 (m, 1H, Hα-15), 2.09 (m, 1H, 
Hα-16), 2.20‒2.33 (m, 2H, Hα-6, Hβ-6), 2.40 (m, 1H, Hβ-2), 2.46 (dd, J = 19.5, 9 Hz, 1H, 
Hβ-16), 2.49 (m, 1H, Hα-2), 4.28 (br.d, J = 5 Hz, 2H, CH3CH2), 6.05 (s, 1H, H-4), 8.03 (br.s, 
1H, NH). 
13
C NMR (125 MHz, CDCl3): 220.7 (s, C-17), 161.1 (s, C-5), 154.4 (s, C=O), 154.3 
(s, C-3), 110.2 (d, C-4), 61.9 (t, CH3CH2), 54.1 (d, C-9), 50.9 (d, C-14), 47.6 (s, C-13), 39.2 
(s, C-10), 36.5 (t, C-1), 35.8 (d, C-16), 35.3 (t, C-8), 33.1 (t, C-6), 31.4 (t, C-12), 31.2 (t, C-7), 
27.8 (t, C-2), 21.8 (t, C-15), 20.4 (t, C-11), 18.2 (q, C-19), 14.6 (q, CH3CH2), 13.7 (q, C-18).   
 
2.1.2.3. (E)-Ethyl (17-oxoandrosta-4,9(11)-dien-3-ylidene)hydrazinecarboxylate (5c). The 
title compound was obtained starting from (E)-androsta-4,9(11)-diene-3,17-dione 3-
semicarbazone (2c-E) (340 mg). Elution with PhMe/EtOAc (65/35) gave 5c (198 mg, 53.5%). 
Rf = 0.40 (PhMe:EtOAc = 6:4, double development). Crystallization from the mixture 
CHCl3/CH3OH did not afford crystals suitable for X-ray analysis. Mp > 77 °C (decomp.). IR 
(ATR/cm
-1
): 3258, 2964 and 2928 (NH), 1735 (C=O), 1517,  1449 (C=N), 1231, 1057. 
1
H-
NMR (500 MHz, CDCl3): 0.87 (s, 3H, H3C-18), 1.11 (qd, J = 12.5, 3.5 Hz, 1H, Hα-7), 1.24 
(s, 3H, H3C-19), 1.32 (t, J = 6.5 Hz, 3H, CH3CH2), 1.50 (m, H-14), 1.61 (m, 1H, Hβ-15), 1.89 
(td, J = 13, 5 Hz, 1H, Hα-12), 2.03‒2.09 (m, 3H, Hα-1, Hβ-7, Hβ-12), 2.11 (m, 1H, Hβ-1), 
2.13 (m, 1H, Hα-15), 2.15 (m, 1H, Hα-16), 2.24 (m, 1H, Hβ-2), 2.34 (m, 1H, H-8), 2.27 (t, J 
= 3 Hz, 1H, Hα-6), 2.48 (m, 1H, Hβ-16), 2.51 (m, 1H, Hβ-6), 2.58 (dt, J = 16.5, 3.5 Hz, 1H, 
Hα-2), 4.29 (br.d, J = 6 Hz, 2H, CH3CH2), 5.52 (d, J = 5 Hz, 1H, H-11), 6.02 (s, 1H, H-4), 
7.72 (s, 1H, NH). 
13
C NMR (125 MHz, CDCl3): 221.4 (s, C-17), 153.5 (s, C-5), 150.8 (s, 
  
C=O), 150.7 (s, C-3), 146.0 (s, C-9), 121.5 (d, C-4), 117.2 (d, C-11),  61.9 (t, CH3CH2), 48.2 
(d, C-14), 46.0 (s, C-13), 40.3 (s, C-10), 37.3 (t, C-8), 36.4 (d, C-16), 33.6 (t, C-1), 32.8 (t, C-
12), 32.1 (t, C-6), 31.4 (t, C-7), 26.8 (q, C-19), 22.8 (t, C-15), 20.5 (t, C-2), 14.7 (q, CH3CH2), 
14.0 (q, C-18).  Anal. calcd for C22H30N2O3 × 0.3 CHCl3 × 0.3 C7H8: C 67.18; H 7.54; N 6.35;  
Found: C 67.35; H 7.66; N 6.50. 
 
2.1.2.4. (E)-Ethyl (11α-hydroxy-17-oxoandrost-4-en-3-ylidene)-hydrazinecarboxylate (5d). 
The title compound was obtained starting from 11α-hydroxyandrost-4-ene-3,17-dione 3-
semicarbazone (2d) (E/Z = 8:2) (360 mg). Elution with PhMe/EtOAc (5/5) gave 5d (E/Z = 
8:2), (161.8 mg, 41.7%). Rf = 0.49 (PhMe:EtOAc = 6:4). Mp > 120 °C (decomp.). IR 
(ATR/cm
-1
): 3450 (OH), 3219 (NH), 2935, 1733 (C=O), 1527 and 1458, (C=N), 1236, 1026, 
736. Anal. calcd for C22H32N2O4  × 0.9 CHCl3: C 55.46; H 6.69; N 5.65; Found: C 55.36; H 
6.21; N 5.21. 
 
(5d-E) from the mixture E/Z = 8:2. 
1
H-NMR (500 MHz, CDCl3): 0.93 (s, 3H, H3C-18), 
1.03‒1.13 (m, 2H, Hα-7, H-9), 1.21 (s, 3H, H3C-19), 1.28‒1.35 (m, 4H, CH3CH2, Hβ-12), 
1.39 (m, 1H, H-14), 1.54 (t,  J = 12 Hz, Hβ-15), 1.64 (br.d, J = 11Hz, H-8), 1.715 (td, J = 
13.5, 4.5 Hz, Hβ-1), 1.88 (br.d, J = 14 Hz, Hβ-7), 1.96 (m, 1H, Hα-15), 2.13 (m, 3H, Hβ-2, 
Hα-12, Hα-16), 2.26‒2.35 (m, 2H, Hα-6, Hβ-6), 2.39‒2.51 (m, 2H, Hα-2, Hβ-16), 2.67 (br.d, 
J = 13.5 Hz, Hα-1), 4.02 (br.s, 1H, Hβ-11),  4.27 (br.s, 2H, CH3CH2), 6.00 (s, 1H, H-4), 7.83 
(s, 1H, NH). 
13
C NMR (50 MHz, CDCl3): 219.1 (s, C-17), 155.2 (s, C-5), 154.3 (s, 
C=O),151.2 (s, C-3), 122.1 (d, C-4), 68.9 (d, C-11), 61.9 (t, CH3CH2), 59.1 (d, C-9), 50.2 (d, 
C-14), 48.1 (s, C-13), 42.9 (t, C-12), 39.1 (s, C-10), 36.0 (t, C-1), 35.8 (t, C-16), 34.8 (d, C-8), 
32.9 (t, C-6), 30.5 (t, C-7), 21.8 (t, C-15), 20.5 (t, C-2), 18.6 (q, C-19), 14.7 (q, CH3CH2), 
14.7 (q, C-18).  
 
(5d-Z) from the mixture E/Z = 8:2.
 1
H-NMR (500 MHz, CDCl3): 0.93 (s, 3H, H3C-18), 
1.03‒1.13 (m, 2H, Hα-7, H-9), 1.27 (s, 3H, H3C-19), 1.28‒1.35 (m, 4H, CH3CH2, Hβ-12), 
1.51 (m, 1H, H-14), 1.54 (t,  J = 12 Hz, Hβ-15), 1.64 (br.d, J = 11Hz, H-8), 1.82 (m, 1H, Hβ-
1), 1.93 (m, 1H, Hβ-7), 1.96 (m, 1H, Hα-15), 2.13 (m, 3H, Hβ-2, Hα-12, Hα-16), 2.35‒2.39 
(m, 2H, Hα-6, Hβ-6), 2.39‒2.47 (m, 2H, Hα-2, Hβ-16), 2.49 (m, Hα-1), 4.02 (br.s, 1H, Hβ-
11), 4.27 (br.s, 2H, CH3CH2), 6.05 (s, 1H, H-4), 8.03 (s, 1H, NH). 
13
C NMR (50 MHz, 
CDCl3): 218.9 (s, C-17), 161.0 (s, C-5), 154.3 (s, C=O), 150.3 (s, C-3), 111.1 (d, C-4), 68.7 
(d, C-11), 61.9 (t, CH3CH2), 59.5 (d, C-9), 50.1 (d, C-14), 48.1 (s, C-13), 42.8 (t, C-12), 40.7 
  
(s, C-10), 38.1 (t, C-1), 35.8 (t, C-16), 34.6 (d, C-8), 33.9 (t, C-6), 31.0 (t, C-7), 27.8 (t, C-2), 
21.8 (t, C-15), 19.0 (q, C-19), 14.7 (q, CH3CH2), 14.7 (q, C-18).  
 
2.1.2.5. (E)-Ethyl (20-oxopregn-4-en-3-ylidene)hydrazinecarboxylate (5e). The title 
compound was obtained starting from (E)-progesterone 3-semicarbazone (2e-E) (370 mg). 
Elution with PhMe/EtOAc (7/3) gave 5e (194.8mg, 48.7%). Rf = 0.48 (PhMe:EtOAc = 6:4, 
double development). Crystallization from diisopropyl ether did not afford crystals suitable 
for X-ray analysis. Mp = 83.7 °C. IR (ATR/cm
-1
): 3275, 2937 (NH), 1701 (C=O), 1518,  1449 
(C=N), 1267, 1047. 
1
H-NMR (500 MHz, DMSO-d6): 0.56 (s, 3H, H3C-18), 0.82 (td, J = 11.5, 
2.5 Hz, 1H, H-9), 0.90 (br.q, J = 12 Hz, 1H, Hα-7), 1.00 (s, 3H, H3C-19), 1.09‒1.17 (m, 2H, 
H-14, Hα-16), 1.21 (t, J = 7 Hz, 3H, CH3CH2), 1.25‒1.48 (m, 4H, Hα-1, H-8, Hβ-11, Hα-12), 
1.50‒1.60 (m, 2H, Hα-11, Hβ-15), 1.62 (m, 1H, Hβ-16), 1.72 (br.d, J = 11.5 Hz, 1H, Hβ-7), 
1.86 (br.d, J = 13 Hz, 1H, Hβ-1), 1.94‒2.03 (m, 3H, Hβ-2, Hβ-12, Hα-15), 2.06 (s, 3H, H3C-
21),  2.20 (t, J = 4 Hz, 1H, Hα-6), 2.29 (m, 1H, Hβ-6), 2.56 (t, J = 9 Hz, 1H, H-17), 2.70 (d, J 
= 17 Hz, 1H, Hα-2), 4.10 (q, J = 7 Hz, 2H, CH3CH2), 5.75 (s, 1H, H-4), 9.78 (s, 1H, NH). 
13
C 
NMR (50 MHz, DMSO-d6): 208.6 (s, C-20), 154.2 (s, C-5 and C=O), 151.3 (s, C-3), 120.9 (d, 
C-4), 62.6 (d, C-17), 60.2 (t, CH3CH2), 55.4 (d, C-14), 53.0 (d, C-9), 43.3 (s, C-13), 38.0 (t, 
C-12), 37.0 (s, C-10), 35.2 (d, C-8), 34.5 (t, C-1), 31.8 (t, C-7), 31.6 (t, C-6), 31.1 (q, C-21), 
24.0 (t, C-16), 22.2 (t, C-15), 20.9 (t, C-11), 20.7 (t, C-2), 17.4 (q, C-19), 14.6 (q, CH3CH2), 
13.0 (q, C-18).  Anal. calcd for C24H38N2O3: C 71.96; H 9.06; N 6.99; Found: C 72.33; H 
9.26, N 6.44. 
 
2.1.3. Synthesis of ethyl (17-oxo-19-norandrost-4-en-3-ylidene)hydrazinecarboxylate (5a) 
from 19-norandrost-4-ene-3,17-dione 3-semicarbazone (2a) without  ethyl chloroacetate, 
using ethanol as nucleophile 
Solution of 19-norandrost-4-ene-3,17-dione 3-semicarbazone (2a) (330 mg, 1 mmol) 
in absolute ethanol (30 mL, 0.5 mol) was heated under reflux (80 °C)  for 48 h, until the 
reaction was completed, monitored by TLC. Evaporation of the solvent afforded desired 
product (170 mg, 47.3 %) as a pale yellow solid which was purified by flash column 
chromatography. After several consecutive chromatographies (elution with PhMe/EtOAc 
(65/35)) diastereomerically pure major isomer 5a-E was obtained (98.6 mg, 27.4%). The rest 
was E/Z mixture (2:8) of 5a (49.7 mg, 13.8 %). 
 
  
(5a-E): 
1
H-NMR (500 MHz, CDCl3): 0.78 (br.d, J = 11 Hz, 1H, H-9), 0.90 (s, 3H, H3C-18), 
1.04 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.23‒1.35 (m, 7H, Hα-1, Hβ-11, Hβ-12, H-14, CH3CH2), 
1.42 (q, J = 10.5 Hz, 1H, H-8), 1.54 (dbr.sd, J = 3 Hz, 1H, Hβ-15), 1.78‒1.90 (m, 3H, Hβ-7, 
Hα-11, Hα-12), 1.92‒2.00  (m, 2H, H-10, Hα-15), 2.02 (t, J = 5 Hz, 1H, Hβ-2), 2.08 (dd, J = 
18.5, 9 Hz, 1H, Hα-16), 2.11‒2.22 (m, 2H, Hβ-1, Hα-6), 2.38‒2.47 (m, 2H, Hβ-6, Hβ-16), 
2.53 (dt, J = 16.5, 4 Hz, 1H, Hα-2), 4.26 (br.d, J = 5.5 Hz, 2H, CH3CH2), 6.08 (s, 1H, H-4), 
7.69 (s, 1H, NH). 
13
C NMR (125 MHz, CDCl3): 220.9 (s, C-17), 154.0 (s, C=O), 151.4 (s, C-
3), 150.5 (s, C-5), 122.2 (d, C-4), 61.9 (t, CH3CH2), 50.4 (d, C-14), 49.6 (d, C-9), 47.8 (s, C-
13), 41.6 (d, C-10), 40.1 (d, C-8), 35.8 (t, C-16), 34.8 (t, C-6), 31.5 (t, C-12), 30.1 (t, C-7), 
26.1 (t, C-1), 26.0 (t, C-11), 22.2 (t, C-2), 21.8 (t, C-15), 14.7 (q, CH3CH2), 13.9 (q, C-18).  
 
(5a-Z) from the mixture E/Z = 2:8. 
1
H-NMR (500 MHz, CDCl3): 0.81 (br.d, J = 10.5 Hz, 1H, 
H-9), 0.92 (s, 3H, H3C-18), 1.08 (qd, J = 12.5, 3.5 Hz, 1H, Hα-7), 1.24 (m, 2H, Hβ-11, Hβ-
12), 1.28 (m, 1H, H-14), 1.29‒1.36 (m, 4H, Hα-1, CH3CH2), 1.48 (qd, J = 11, 2.5 Hz, 1H, H-
8), 1.57 (dtd, J = 3.5 Hz, 1H, Hβ-15), 1.83 (dd, J = 8.5, 3 Hz, 1H, Hα-12), 1.87‒2.00 (m, 3H, 
Hβ-7, Hα-11, Hα-15), 2.04  (m, 1H, H-10,), 2.10 (dd, J = 19.5, 9 Hz, 1H, Hα-16), 2.18 (m, 
1H, Hβ-1), 2.27 (td, J = 12, 3.5 Hz, 2H, Hβ-2, Hα-6), 2.42‒2.51 (m, 2H, Hβ-6, Hβ-16), 2.54 
(dt, J = 14, 3.5 Hz, 1H, Hα-2), 4.275 (br.d, J = 5 Hz, 2H, CH3CH2), 6.14 (s, 1H, H-4), 8.05 
(br.s, 1H, NH). 
13
C NMR (125 MHz, CDCl3): 220.6 (s, C-17), 156.7 (s, C-3), 154.6 (s, C=O), 
150.5 (s, C-5), 111.1 (d, C-4), 61.9 (t, CH3CH2), 50.2 (d, C-14), 50.0 (d, C-9), 47.8 (s, C-13), 
43.3 (d, C-10), 40.1 (d, C-8), 35.9 (t, C-6), 35.8 (t, C-16), 31.3 (t, C-12), 30.5 (t, C-2), 30.5 (t, 
C-7), 27.4 (t, C-1), 25.5 (t, C-11), 21.7 (t, C-15), 14.7 (q, CH3CH2), 13.8 (q, C-18).  
 
2.2. Biology 
 
2.2.1. Cytotoxicity assay 
 The cytotoxic activity of the compounds was evaluated against three human 
malignant cell lines: cervical adenocarcinoma (HeLa), chronic myelogenous leukemia (K562) 
and acute T-cell leukemia Jurkat cell line. HeLa (2,000 cells per well) were seeded into 96-
well microtiter plates and 20 h later, after the cell adherence, five different concentrations of 
tested compounds were added to the cells, except for the control cells to which only nutrient 
medium was added. K562 cells (5,000 cells per well) and Jurkat cells (15,000 cells per well) 
were seeded 2 h before addition of compounds. The cytotoxicity assay procedure has been 
described elsewhere [20,21]. Stock solutions of compounds were prepared in DMSO at a 
  
concentration of 10 mM. For each experiment, the solutions were diluted with nutrient 
medium and applied to cells to various final concentrations ranging from 6.25 μM to 100 μM 
or 12.50 μM to 200 μM. The final concentration of DMSO solvent never exceeded 1%, which 
was non-toxic to the cells. The positive control was chemotherapy drug cisplatin. Survival of 
cells was determined by MTT assay after 72 h of continuous action, according to the method 
of Mosmann [22], which was modified by Ohno and Abe [23] and described in detail in our 
previous studies [18-21]. 
All tested cell lines were obtained from the American Type Culture Collection 
(Manassas, VA, USA).  
 
2.2.2. Antimicrobial activity 
The antibacterial activity was evaluated using two different strains of bacteria, 
one Gram-positive bacteria: Clostridium sporogenes (ATCC 19404) and one Gram-
negative bacteria: Pseudomonas aeruginosa (ATCC 9027). Antibacterial activity was 
determined by well diffusion method [24]. In each Petri dish (90 mm diameter) 22 mL 
of Nutrient agar (Hi Media, Mumbai, India) and 100 µL of bacterial suspension (10
6
 
cells/dish) were added. Eight millimeter diameter well was then punched carefully 
using a sterile cork borer and 100 µL of test substance (1 mg/100 µL DMSO) were 
added into each labeled well. Amikacin (30 µg/100 µL H2O) was used as positive 
control, while 100 µL of water and DMSO served as negative controls. After the 
inoculation of the organisms, compounds and controls, the plates were incubated for 24 
h at 37 °C. Zones of inhibition were recorded in millimeters. 
The fungus tested was Aspergillus brasiliensis (ATCC 16404). Sabouraud 
dextrose agar (Torlak, Belgrade, Serbia) was prepared according to the manufacturer’s 
instruction. In each sterile Petri dish (90 mm diameter) 22 mL of previously prepared 
agar suspension was poured and 100 µL of fungus (10
5
 spores/dish) was added. Eight 
millimeter diameter well was punched using a sterile cork borer. Into each well 100 µL 
of test substance (1 mg/100 µL DMSO) were added. Nystatin (30 µg/100 µL DMSO) 
was used as a positive control, while 100 µL of DMSO served as a negative control. 
The plates were incubated for 48 h at 24 °C. Antifungal activity was determined by 
measuring the diameter of inhibition zone in millimeters. 
 
2.2.3. The brine shrimp test  
  
The brine shrimp test of toxicity was performed against freshly hatched nauplii 
of Artemia salina [25]. The method was slightly modified by our team and described 
earlier [19]. The compounds were dissolved in DMSO and diluted by artificial 
seawater until range of concentrations (0.01‒0.50 mg/mL) was obtained. The final 
concentration of DMSO was 1% and did not cause changes of viability of nauplii. The 
number of nauplii was approximately 20. Surviving nauplii were counted after 24 h, 
and LC50 (concentration lethal to 50% of the nauplii) were determined after statistical 
analysis. All the tests were performed in triplicate. 
 
3. Results and Discussion 
 
3.1. Chemistry 
The target compounds, new steroidal mono- and bis(semicarbazones), were synthesized by a 
general procedure starting from steroids (1a–e) and semicarbazide in dried ethanol (Scheme 
1). 
 
 
 
Scheme 1 
 
  
In our previous work [21], we found that regardless of the molar ratio of steroids and 
thiosemicarbazide (equimolar or 1:2, respectively), a mixture of mono- and 
bis(thiosemicarbazones) was always obtained. Therefore, this time, the reaction was 
conducted with a small excess of reagent until complete consumption of steroids 1a–e, as 
monitored by thin layer chromatography (TLC), giving 3-semicarbazones 2a‒e in the yields 
of 15.1‒76% and 3,17- or 3,20-bis(semicarbazones) 3a‒e in the yields of 10.2‒24.2% (see 
Experimental). Additionally, in the reaction of 11α-hydroxyandrost-4-ene-3,17-dione (2d), 
17-mono-semicarbazone 4d was obtained in the yield of 13.6%. The structures of the 
synthesized compounds were confirmed by elemental analysis, HRMS, 
1
H NMR, 
13
C NMR 
and IR spectroscopy. For the detailed characterization and complete 
1
H and 
13
C assignments 
of each compound and isomers (where they were obtained), the 2D NMR (HSQC, HMBC, 
NOESY, COSY) experiments were performed (Supporting Material). 
 
The NMR analysis for the obtained compounds revealed the presence of two diastereoisomers 
(Z and E) with different configurations in the hydrazone moiety at the C-3 position, 
determined on the basis of the NOESY correlations, while at C-17 and C-20 (for progesterone 
derivative) only one isomer was obtained. The ratio of the isomers was deduced by comparing 
the peak areas of the H-4 and H–N–N=C(3) in the corresponding 1H NMR spectra. 
 
The 
1
H NMR spectrum of 2a showed two singlets for olefinic H-4 proton. In (Z)-isomer H-4 
appears at lower field (s, 6.52 ppm), than that in the (E)-isomer (s, 5.83 ppm) due to the 
orientation of the of semicarbazone moiety at C-3. For the same reason Hα-2 proton in (E)-
isomer resonates well-separated downfield from the other ring protons as dt at 2.68 ppm. 
Also, there were broad singlets for the H2N protons, at δ 6.20 ppm and 6.15 ppm and two 
singlets for amide H‒N proton at δ 9.11 ppm and 9.33 ppm for (E)- and (Z)-isomer, 
respectively. The characteristic signals in the 
13
C NMR spectrum were: at δ 22.6 ppm and 
30.0 ppm (C-2), 121.9 ppm and 112.9 ppm (C-4), 147.2 ppm and 144.5 ppm (C-3) and 148.5 
ppm and 153.7 ppm (C-5) for (E)- and (Z)-isomer, respectively. The presence of the NOESY 
correlations between amide proton at 9.11 ppm and Hα-2 at 2.68 ppm, Hβ-2 at 1.90 ppm,  
and, although weak, correlations of the same proton with H-4 at 5.82 ppm and  H2N at 6.20 
ppm provided evidence for the E-configuration, while in the (Z)-isomer N-H proton at δ 9.33 
ppm showed NOESY cross-peaks with H-4 at 6.52 ppm and H2N at 6.15 ppm and no 
correlations were observed with the protons at C-2 (Fig. 1). 
 
  
Figure 1. 
 
Almost the same 
1
H and 
13
C NMR signal arrangements were observed for all synthesized 
semicarbazones 2a‒e. 
 
3,17-Bis(semicarbazone) 3a was also obtained as a mixture of the two isomers differing only 
in the configuration at C(3)=N double bond. The 
1
H NMR spectrum of 3a contained two 
singlets for olefinic H-4 proton at δ 5.83 ppm and 6.51 ppm, two broad singlets for the H2N 
protons from the semicarbazone moiety at C-3 at δ 6.20 ppm and 6.14 ppm and two singlets 
for N-H proton also from the semicarbazone moiety at C-3 confirmed by the HMBC 
correlations of the H–N protons with C-3 (9.06 ppm/147.3 ppm for 3E, and 9.29 ppm/144.6 
ppm for 3Z). One broad singlet for H2N from semicarbazone moiety at C-17 appeared at δ 
6.09 ppm for both 3E- and 3Z-isomer,  as well as the singlet for H‒N proton at δ 8.71 ppm 
with  HMBC correlation with C-17 (8.71 ppm/163.0 ppm) indicating that in C-17 position 
only one isomer was obtained (Fig. 1) which was also confirmed by comparing the peak areas 
of these signals. The E configuration of the C(17)=N double bond was evidenced on the basis 
of the NOESY correlation of NH at 8.71 ppm with Hα-16 at 2.14 ppm and the absence of any 
correlation with the CH3-18. This was expected because the strong steric repulsion between 
CH3-18 from sterane skeleton and semicarbazone moiety at C-17 prevents the formation of 
(Z)-isomer (Fig. 1) [21]. 
This can be also applied to all synthesized 3,17-bis(semicarbazones) 3a‒d. 
 
 In the case of compound 3e, pregn-4-ene-3,20-dione bis(semicarbazone), possible rotation 
around C(17)–C(20) axis and presence of CH3-21 methyl group must be considered which is 
why it could be assumed that due to the strong steric hindrance the formation of (Z)-isomer in 
semicarbazone moiety at C-20 is impossible. Anyhow, the NOESY correlation between 
amide proton from hydrazone moiety at 8.78 ppm and CH3-21 at 1.76 ppm and the absence of 
any correlation with CH3-18 or H2C-16 protons provided unambiguous evidence for E-
configuration (Fig. 2). In addition, inspection of the Dreiding models suggests that this 
correlation, regardless of the rotation around C(17)–C(20) axis, is possible only when the 
geometry of C(20)=N double bond is E. 
 
 
Figure 2. 
  
When thus obtained semicarbazones 2a‒e as a mixture of both isomers (E and Z) were 
subjected to ethyl chloroacetate in boiling absolute ethanol containing anhydrous sodium 
acetate, which usually acts as the cyclizing agent, the expected intramolecular 
cyclocondensation reaction leading to formation of 1,3-oxazolidin-4-one did not occur. 
Instead, ethyl hydrazinecarboxilates 5a‒e were obtained (Scheme 2).  
 
 
 
Scheme 2 
 
The structure of compounds 5a‒e was deduced from their NMR spectral data where two 
sets of NMR resonances suggest that these new derivatives were, as expected, obtained as a 
mixture of isomers. Most of the signals assigned to the carbon atoms forming sterane sceleton 
in compounds 2a‒e (E and Z) and 5a‒e (E and Z), did not differ significantly. Thus, 1H/13C 
NMR spectra of
  
5a showed two signals for HC-4 at δ 5.86/121.7 ppm and 6.51/112.9 ppm, 
two signals for Hα-2 proton at δ 2.71/22.9 ppm and 2.29/30.0 ppm as well as two signals for 
NH in 
1
H NMR spectra at δ 9.78 ppm and 9.98 ppm for (E)- and (Z)-isomer, respectively, 
confirming the presence of two diastereoisomers with different configurations at C(3)=N 
double bond. However, significant difference was observed for the amino group from 
semicarbazone moiety in compounds 2a‒e (at δ 6.20 ppm and 6.15 ppm for (E)- and (Z)-
isomer, respectively), the absence of which was evident in 
1
H NMR spectra of compounds 
5a‒e. Instead, new 1H triplets/13C quartets at δ 1.31/14.6 ppm and 1H quartets/13C triplets at 
4.28/61.9 ppm appeared indicating the indroduction of the new CH3CH2OCO moiety. Also, in 
the HMBC NMR spectrum of 5a compound (recorded in DMSO) the presence of cross peaks 
between carbonyl C-atom at δ 154.1 ppm and NH proton at δ 9.78 ppm as well as methylene 
protons at δ 4.09 ppm confirmed the proposed structure (Fig. 3). In addition, in the IR spectra 
of
  
5a‒e the absorption bands for the primary amino group from semicarbazone moiety at 
about 3450 cm
–1
 were missing. Finally, the molecular formulas of 
 
5a‒e were established on 
the basis of microanalyses data. 
 
  
Distinguishing between Z- and E-configuration in the stereoisomeric pairs of 5a-e was 
possible on the basis of the NMR chemical shifts of HC-4, H2C-2  and NH and by comparison 
of the spectral data with those of the parent steroidal semicarbazones 2a‒e as well as by the 
presence (for E) and the absence (for Z) of the NOESY correlations between amide  proton 
and protons at C-2. In the (Z)-isomer N-H proton showed NOESY cross-peak with H-4 
(Figure 3). 
  
Figure 3. 
 
Regarding compounds 5b‒e, almost the same patterns of 1H and 13C NMR spectra were 
observed as in the spectra for 5a (Experimental and Supplementary).  
The mechanism of the formation of these carbazate derivatives has already been 
described as a simple exchange reaction using semihydrazone and alcohols upon heating at 
60‒150 °C [26].  
In order to prove this, we prepared the experiment with 19-norandrost-4-ene-3,17-dione 
3-semicarbazone (2a) in boiling absolute ethanol without presence of ethyl chloroacetate and 
sodium acetate. After 48 h of reflux and evaporation of the solvent compound 5a was 
obtained in the yield of 47% (Scheme 3).  
 
 
 
Scheme 3 
 
3.2. Biological evaluation 
3.2.1. Cytotoxic activity 
 The in vitro cytotoxic activity of the new steroidal semicarbazone derivatives was 
tested against two human malignant cell lines which were found to be the most sensitive to 
the cytotoxic action of our previously synthesized, corresponding steroidal 
thiosemicarbazones [1,21], chronic myelogenous leukemia K562 and human cervical 
adenocarcinoma HeLa cells. Since our previously investigated compounds [1,21] showed the 
  
best activity against K562 cells, in this study the activity towards another leukemia cell line 
was also investigated. For that purpose a human acute T-cell leukemia Jurkat cell line was 
selected. Cisplatin (CDDP) was employed as the positive control. The results from MTT 
assays are presented in Table 1. It should be noted that compounds 3e and 5d were poorly 
soluble in DMSO, and their activity was not possible to examine.  
 
Table 1. 
 
Unexpectedly, almost all investigated compounds exhibited a very poor cytotoxic 
action against K562 cells. Compounds 2d, 3d and 4d were practically inactive, while the 
other compounds tested exerted very weak cytotoxic activity with IC50 values from 
71.6‒163.7 µM. The exception was compound 5e which showed moderate activity against 
this cell line with IC50 of 40.5 µM. The same compound exhibited the best cytotoxic action 
towards Jurkat cells with IC50 of 31.8 µM. Again, compounds 2d, 3d and 4d were the least 
active with IC50 values from 126.3‒180.1 µM. Also, all other investigated compounds exerted 
more pronounced cytotoxic activity against this leukemia cell line (IC50 values from 
51.2‒119.6 µM) but still very low compared to cisplatin.  
 
Of all examined malignant cell lines, HeLa cells were the most sensitive to the 
cytotoxic action of the six newly synthesized steroid derivatives 2c, 2e, 3b, 3c, 5c, and 
5e. The best cytotoxic activity was exhibited by compounds 2e, 3c and 5e with IC50 
values of 27.7, 21.4 and 22.4 µM, respectively, while compounds 2c, 3b and 5c 
exerted moderate activity with IC50 of 42.7, 57.2 and 62.5 μM, respectively. 
Compounds 2a, 2b, 3a, 5a and 5b showed very weak activity against HeLa cells with 
IC50 from 85.6–152.4 μM while compounds 2d, 3d and 4d again proved to be almost 
inactive. 
 The results mentioned above indicate that of examined compounds 
progesterone derivatives 2e and 5e exhibited the highest cytotoxic actions against 
tested malignant cell lines. Compounds 2c, 3c and 5c, derived from androsta-4,9(11)-
diene-3,17-dione showed moderate cytotoxic activity, while androstene and 19-nor-
androstene derivatives were the least active. Compounds 2d, 3d and 4d, 11α-hydroxy 
semicarbazones, were practically inactive against all tested malignant cell lines and these 
findings are in accordance with our previous results obtained for other 11α-hydroxy 
derivatives [1,21], and corrooborates the hypothesis that the substitution of a hydrogen atom 
  
by proton-donating OH-group in 11α-position led to a dramatic decrease in activity [1,21]. 
However, these results demonstrate that new steroidal mono- and bis(semicarbazones) and 
their derivatives were significantly less active than corresponding steroidal 
thiosemicarbazones.  
 
 
3.2.2. Antimicrobial activity 
The in vitro antimicrobial activity of all new compounds was tested against Gram-positive 
bacteria Clostridium sporogenes and Gram-negative bacteria Pseudomonas aeruginosa and 
against one fungal species Aspergillus brasiliensis by agar well diffusion method.  
All synthesized ethyl hydrazinecarboxilates (exception is 5d which was completely 
insoluble in DMSO) as well as compounds 2d, 3a, 3d and 4d exhibited a weak inhibitory 
activity against both tested bacteria. In all cases the inhibition zones were much smaller than 
those for amikacin (Table 2). Also, these compounds were found to have weak antifungal 
activity against A. brasiliensis. However, it should be noted that compounds 5b and 5c 
showed a slightly better activity with approximately the same inhibition zone as nystatin. 
Here, it should be taken into account that the concentration of nystatin, which was used as 
positive control was much lower. 
Table 2. 
 
3.2.3. The brine shrimp test 
 In the brine shrimp test, which has been established as a safe, practical, and economic method 
for the determination of the in vivo bioactivity of synthetic compounds, general toxicity 
against nauplii of the brine shrimp Artemia salina was evaluated. The LC50 values obtained 
for the newly synthesized compounds are shown in Table 3. All examined compounds were 
found to be less toxic when compared to the cisplatin. However, compounds 5b and 5c as 
well as 3d with the best antimicrobial activity, were also found to be the most active in the 
brine shrimp assay. 
Table 3. 
 
4. Conclusion 
Using various 3-oxo-α,β-unsaturated steroids as starting materials, 6 new steroidal mono-
semicarbazones 2a–e and 4d  and 5 bis(semicarbazones) 3a–e were prepared. Mono-
semicarbazones 2a–e were further subjected to ethyl chloroacetate in boiling absolute ethanol 
  
containing anhydrous sodium acetate, which did not lead to the expected intramolecular 
cyclocondensation reaction. Instead, carbazate esters 5a‒e were obtained. The structures of 
the synthesized compounds were confirmed by elemental analysis, HRMS and IR, 
1
H NMR, 
13
C NMR spectroscopy. The thorough NMR analysis indicated the presence of two 
diastereoisomers (Z and E) with different configurations in the hydrazone moiety at the C-3 
position, determined on the basis of the NOESY correlations, while at C-17 and C-20 (for 
progesterone derivatives) only one isomer was obtained. 
 Preliminary screening for the in vitro cytotoxic activity of the new compounds has 
been conducted. Unexpectedly, almost all investigated compounds exhibited a very poor 
cytotoxic action against K562 cells. Towards Jurkat cells tested compounds exerted more 
pronounced cytotoxic activity, while HeLa cells were the most sensitive to the cytotoxic 
action of the six newly synthesized steroid derivatives. Among these compounds 2e, 3c and 
5e were found to have the best but still moderate cytotoxic effects against all malignant cells 
tested. 
 These results demonstrate that new steroidal mono- and bis(semicarbazones) and 
their derivatives were significantly less active than corresponding steroids with 
thiosemicarbazone moiety. Obviously, the replacement of thioxo group with carbonyl group 
in steroidal hydrazone derivatives resulted in dramatic decrease in their cytotoxic activity. 
Similarly, all tested compounds showed weak antimicrobial activities as well as in 
vivo toxicity against brine shrimp Artemia salina. 
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Figure captions 
Scheme 1. Synthesis of new steroidal mono- and bis(semicarbazones) 
 
Scheme 2. Synthesis of new steroidal ethyl hydrazinecarboxilates  
 
Scheme 3. Synthesis of  ethyl (17-oxo-19-norandrost-4-en-3-ylidene)hydrazinecarboxylate 
(5a) from 19-norandrost-4-ene-3,17-dione 3-semicarbazone (2a) without  ethyl chloroacetate, 
using ethanol as nucleophile 
  
Fig. 1. 3D representation of the possible and proposed configuration at C(3)=N and  C(17)=N 
double bonds with key HMBC (H/C ) and NOESY ( ) correlations 
 
Fig. 2. 3D representation of the absolute configuration on C(20)=N double bond in 3e with 
the key NOESY correlations 
 
Fig. 3. 3D representation of the proposed configuration at C(3)=N double bond in compound 
5a with key HMBC (H/C ) and NOESY ( ) correlations 
 
 
 
 
 
  
 
 
 
 
  
 
Table 1. The in vitro cytotoxic activity of compounds 2a‒e, 3a‒e, 4d and 5a‒e (contrentacion 
which induced 50% decrease (IC50) in malignant cell survival) 
Comp. IC50 ± SD (µM) 
HeLa K562 Jurkat 
2a 152.4 ± 7.8 143.8 ± 4.9 74.5 ± 8.0 
2b 100.6 ± 7.8 158.4 ± 4.7 80.1 ± 2.4 
2c 42.7 ± 7.0 95.5 ± 5.1 155.7 ± 4.8 
2d 177.3 ± 19.9 191.5 ± 7.5 126.3 ± 10.3 
2e 27.7 ± 6.3 81.5 ± 4.7 51.2 ± 5.7 
3a 85.6 ± 15.7 91.7 ± 0.1 76.9 ± 2.5 
3b 57.2 ± 16.0 163.7 ± 19.3 119.6 ± 14.6 
3c 21.4 ± 3.2 71.6 ± 4.7 87.4 ± 3.5 
3d 189.9 ± 17.5 199.2 ± 1.4 169.0 ± 2.7 
3e / / / 
4d 192.4 ± 6.6 191.3 ± 7.9 180.1 ± 18.1 
5a 144.0 ± 15.2 112.7 ± 7.1 69.8 ± 2.2 
5b 132.5 ± 17.5 100.0 ± 8.6 75.4 ± 4.4 
5c 62.5 ± 4.3 113.0 ± 12.8 75.8 ± 9.6 
5d / / / 
5e 22.4 ± 1.9 40.5 ± 4.1 31.8 ± 0.1 
SC*
 
>200 >200 >200 
CDDP
 
4.6 ± 0.1 
 
6.0 ± 0.1 
 
3.4 ± 0.2 
*Semicarbazide 
 
 
 
 
Table 2. Antimicrobial activity of the investigated compounds  tested by agar well diffusion 
method 
Comp. 
Inhibition zone (mm) 
C. sporogenes P. aeruginosa A. brasiliensis 
2a / / / 
2b / / / 
2c / / / 
2d 12 10 10 
2e / / / 
3a 10 10 10 
3b / / / 
3c / / / 
  
3d 16 14 10 
3e / / / 
4d 10 10 10 
5a 10 10 12 
5b 18 16 30 
5c 12 14 28 
5d / / / 
5e 12 10 10 
Amikacin 22 20 / 
Nystatin 
 
/ / 30 
 
 
 
Table 3. Brine shrimp lethality test results (LC50 values of the cytotoxic activity for the 
investigated compounds against A. salina) 
Comp. LC50 (mM) 
2a 0.124 
2b 0.172 
2c 0.196 
2d 0.134 
2e 0.135 
3a 0.179 
3b 0.120 
3c 0.158 
3d 0.094 
3e / 
4d 0.147 
5a 0.122 
5b 0.027 
5c 0.032 
5d / 
5e 0.151 
CDDP 0.006 
 
 
Highlights 
 The synthesis of new steroidal mono- and bis(semicarbazones) was performed 
 The new carbazate esters were obtained 
 The structures were determined by IR, NMR, HRMS and elemental analysis 
 The antimicrobial and cytotoxic activities of the compounds were tested 
  
 The replacement of thioxo group with carbonyl group in steroidal hydrazone 
derivatives resulted in decrease in their biological activity 
 
 
